Kepos Capital’s Takeda Pharmaceutical TAK Stock Holding History

Kepos Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-75,000	Closed	-$1.26M	–	400
2018 Q4	$1.26M	Buy	+75,000	New	+$1.27M	0.1%	192

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Kepos Capital's TAK Position: Q1 2019 in Review

Kepos Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2019, closing a stake of 75,000 shares — an estimated $1.26M sold.

Kepos Capital first reported a position in TAK in Q4 2018 and held it in 1 quarter. The position peaked at $1.26M in Q4 2018. 390 funds tracked by Wall St. Rank hold TAK as of Q1 2019.

Kepos Capital reported no remaining Takeda Pharmaceutical position as of Q1 2019 after selling out during the quarter.
Kepos Capital sold 75,000 Takeda Pharmaceutical shares in Q1 2019, an estimated $1.26M.
Kepos Capital first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 1 quarter.
Kepos Capital's Takeda Pharmaceutical position peaked at $1.26M in Q4 2018.
390 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2019.

Based on Kepos Capital's 13F filing for Q1 2019, filed 13 May 2019.